Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4505-4513

  Letsch, Markus ^a,b   Schally, Andrew V ^a,c   Szepeshazi, Karoly ^a   Halmos, Gabor ^a   Nagy, Attila ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b St Johanns Spital   (Austria)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DOXORUBICIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN;

ADVANCED CANCER; ANDROGEN INSENSITIVITY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; APOPTOSIS; ARTICLE; BINDING SITE; CANCER HORMONE THERAPY; CASTRATION; CELL PROLIFERATION; CLINICAL RESEARCH; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; GROWTH INHIBITION; HORMONE SENSITIVITY; LIGAND BINDING; LUTEINIZING HORMONE RELEASE; MALE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; XENOGRAFT;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOPLASMS, HORMONE-DEPENDENT; PEPTIDE FRAGMENTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, LHRH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANSPLANTATION, HETEROLOGOUS; TRIPTORELIN; TUMOR CELLS, CULTURED;

EID: 0141891453     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer Statistics, 2002. CA Cancer J. Clin., 52: 23-47, 2002.
2. Morris, M. J., Scher, H. I. Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer (Phila.), 89: 1329-1348, 2000.
3. Schally, A. V., Comaru Schally, A. M., Nagy, A., Kovacs, M., Szepeshazi, K., Plonowski, A., Varga, J. L., and Halmos, G. Hypothalamic hormones and cancer. Front. Neuroendocrinol., 22: 248-291, 2001.
4. Schally, A. V., Comaru-Schally, A. M., Plonowski, A., Nagy, A., Halmos, G., and Rekasi, Z. Peptide analogs in the therapy of prostate cancer. Prostate, 45: 158-166, 2000.
5. 6 analogue of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA, 78: 6509-6512, 1981.
6. Tolis, G., Ackman, D., Stellos, A., Mehta, A., Labrie, F., Fazekas, A. T., Comaru-Schally, A. M., and Schally, A. V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc. Natl. Acad. Sci. USA, 79: 1658-1662, 1982.
7. Oh, W. K. Chemotherapy for patients with advanced carcinoma. Cancer (Phila.), 88: 3015-3021, 2000.
8. Bubendorf, L., Schopfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., Gasser, T. C., and Mihatsch, M. J. Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum. Pathol., 31: 578-583, 2000.
9. Williams, J. F., Muenchen, H. J., Kamradt, J. M., Korenchuk, S., and Pienta, K. J. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate, 44: 275-278, 2000.
10. Petrylak, D. P. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin. Oncol., 3 (Suppl. 27): 24-29, 2000.
11. Sinibaldi, V. J., Carducci, M. A., Moore-Cooper, S., Laufer, M., Zahurak, M., and Eisenberger, M. A. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer, 94: 1457-1465, 2002.
12. Rini, B. I., and Small, E. J. Prostate Cancer Update. Curr. Opin. Oncol., 14: 286-291, 2002.
13. Petrioli, R., Fiaschi, A. I., Pozzessere, D., Messinese, S., Sabatino, M., Marsili, S., Correale, P., Manganelli, A., Salvestrini, F., and Francini G. Weekly epirubicin in patients with hormone-resistant prostate cancer. Br. J. Cancer, 87: 720-725, 2002.
14. Giordano, G. G., Muro, M., Sigalotti, L., and Maio, M. Cancer therapies: basic and clinical perspectives in brain, prostate, and lung tumors: Naples, September, 24-27, 2000. J. Cell. Physiol., 188: 274-280, 2001.
15. Schally, A. V., and Nagy, A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol., 141: 1-14, 1999.
16. Nagy, A., and Schally, A. V. Cytotoxic analogs of luteinizing hormone-releasing hormone (LH-RH): a new approach to targeted chemotherapy. Drugs Future, 27: 359-370, 2002.
17. Halmos, G., Arencibia, J. M., Schally, A. V., Davis, R., and Bostwick D. G. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancer. J. Urol., 163: 623-629, 2000.
18. Schally A. V., Halmos G., Rekasi Z., and Arencibia J. M. The actions of LH-RH agonists and antagonists and cytotoxic analogs on the LH-RH receptors on the pituitary and tumors. In: P. Devroey (ed.), Infertility and Reproductive Medicine Clinica of North America. Philadelphia: Saunders, 12: 17-44, 2001.
19. Qayum, A., Gullik, W., Clayton, R. C., Sikora, K., and Waxman, J. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumor receptors. Br. J. Cancer, 62: 96-99, 2000.
20. Tieva, A., Stattin, P., Wikström, P., Bergh, A., and Damber, J. A. Gonadotropin-releasing hormone receptor expression in the prostate. Prostate, 47: 276-284, 2001.
21. Straub, B., Müller, M., Krause, H., Schrader, M., Goessl, C., Heicappell, R., and Miller, K. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers. Clin. Cancer Res., 7: 234-02343, 2001.
22. Koppan, M., Nagy, A., Schally, A. V., Plonowski, A., Halmos, G., Arencibia, J. M., and Groot, K. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancers in nude mice. Prostate, 38: 151-158, 1999.
23. Plonowski, A., Schally, A. V., Nagy, A., Groot, K., Krupa, M., Navone, N. M., and Logothetis, C. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone releasing hormone AN-207. Cancer Lett., 176: 57-63, 2002.
24. Miyazaki, M., Nagy, A., Schally, A. V., Lamharzi, N., Halmos, G., Szepeshazi, K., Groot, K., and Armatis, P. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J. Natl. Cancer Inst. (Bethesda), 89: 1803-1809, 1997.
25. Szepeshazi, K., Schally, A. V., and Nagy, A. Effective treatment of advanced estrogen independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs. Breast Cancer Res. Treat., 56: 267-276, 1999.
26. Krebs, L. J., Wang, X., Pudavar, H. E., Bergey, E. J., Schally, A. V., Nagy, A., Prasad, P. N., and Liebow, C. Regulation of targeted chemotherapy with cytotoxic luteinizing hormone-releasing hormone analogue by epidermal growth factor. Cancer Res., 60: 4194-4199, 2000.
27. Westphalen, S., Kotulla, G., Kaiser, F., Krauss, W., Werning, G., Elsässer, H. P., Nagy, A., Schultz K-D., Gründker, C., Schally, A. V., and Emons, G. Receptor mediated antiproliferative effects of the cytotoxic LH-RH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int. J. Oncol., 17: 1063-1069, 2000.
28. Jungwirth, A., Schally, A. V., Nagy, A., Pinski, J., Groot, K., Galvan, G., Szepeshazi, K., and Halmos, G. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int. J. Oncol., 10: 877-884, 1997.
29. Arencibia, J., Schally, A. V., Krupa, M., Bajo, A. M., Nagy, A., Szepeshazi, K., and Plonowski, A. Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness Int. J. Oncol., 19: 571-577, 2001.
30. Nagy, A., Schally, A. V., Armatis, P., Szepeshazi, K., Halmos, G., Kovacs, M., Zarandi, M., Groot, K., Miyazaki, M., Jungwirth, A., and Horvath, J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc. Natl. Acad. Sci. USA, 93: 7269-7273, 1996.
31. Gründker, C., Völker, P., Griesinger, F., Ramaswamy, A., Nagy, A., Schally, A. V., and Emons, G. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am. J. Obstet. Gynecol., 187: 528-537, 2002.
32. Djakiew, D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate, 42: 150-160, 2000.
33. Horvath, J. E., Bajo, A. M., Schally, A. V., Kovacs, M., Hebert, F., and Groot, K. Effects of long-term treatment with the luteinizing hormone-releasing hormone (LH-RH) agonist Decapeptyl and the LH-RH antagonist Cetrorelix on the levels of pituitary LH-RH receptors and their mRNA expression in rats. Proc. Natl. Acad. Sci. USA, 99: 15048-15053, 2002.
34. Rekasi, Z., Schally, A. V., Plonowski, A., Czompoly, T., Csernus, B., and Varga, J. L. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. Prostate, 48: 188-199, 2001.
35. Thalmann, G. N., Anezinis, P. E., Chang, S. M., Zhau, H. E., Kim, E. E., Hopwood, V. L., Pathak, S., von Eschenbach, A. C., and Chung, L. W. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res., 54: 2577-2581, 1994.
36. Wu, H. C., Hsieh, J. T., Gleave, M. E., Brown, N. M., Pathak, S., and Chung, L. W. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer, 57: 406-412, 1994.
37. Navone, N. M., Olive, M., Ozen, M., Davis, R., Troncoso, P., Tu, S. M., Johnston, D., Pollak, A., Pathak, S., von Eschenbach, A. C., and Logothetis, C. J. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res., 3: 2493-2500, 1997.
38. Letsch, M., Schally, A. V., Busto, R., Bajo, A. M., and Varga, J. L. Growth hormone releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc. Natl. Acad. Sci. USA, 100: 1250-1255, 2003.
39. Lamharzi, N., Halmos, G., Jungwirth, A., and Schally, A. V. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int. J. Oncol., 13: 429-435, 1998.
40. Bajo, A. M., Schally, A. V., Krupa, M., Hebert, F., Groot, K., and Szepeshazi, K. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc. Natl. Acad. Sci. USA, 99: 3836-3841, 2002.
41. Ehrlich, P. The relationship existing between chemical constitution, distribution, and pharmacological action. In: F. Himmelweite, M. Marquard, and H. Dale (eds.), The Collected Papers of Paul Ehrlich, Vol. 1, pp. 596-618. Elmsford, New York: Pergamon, 1956.
42. Zhao, X. Y., Malloy, P. J., Krishan, A. V., Swami, S., Navone, N. M., Peehl, D. M., and Feldman, D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med., 6: 703-706, 2000.
43. Limonta, P., Dondi, D., Moretti, R. M., Maggi, R., and Motta, M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostate cancer cell line LNCaP. J. Clin. Endocrinol. Metab., 75: 207-212, 1992.
44. Shevrin, D. H., Kukreja, S. C., Ghosh, L., and Lad, T. E. Development of skeletal metastasis by human prostate cancer in athymic nude mice. Clin. Exp. Metastasis, 6: 401-409, 1988.
45. Oesterling, J. E. Prostate specific antigen. Its role in the diagnosis and staging of prostate cancer. Cancer (Phila.), 75: 1795-1804, 1995.
46. Wang, X., Krebs, L. J., Al-Nuri, M., Pudavar, H. E., Ghosal, S., Liebow, C., Nagy, A. A., Schally, A. V., and Prasad, P. N. A. chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy. Proc. Natl. Acad. Sci. USA, 96: 11081-11084, 1999.
47. Wen, Y., Hu, M. C-T., Makino, K., Spohn, B., Bartholomeusz, G., Yan, D-H., and Hung, M. C. HER-2/neu promotes androgen independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res., 60: 6841-6845, 2000.
48. Signoretti, S., Montironi, M., Manola, J., Altimari, A., Tam, C., Bubley, G., Balk, S., Thomas, G., Kaplan, I., Hlatky, L., Hahnfeldt, P., Kantoff, P., and Loda, M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. (Bethesda), 92: 1918-1925, 2000.
49. Myers, R. B., Srivastava, S., Oelschlager, D. K., and Grizzle, W. E. Expression of p160erb B-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst. (Bethesda), 86: 1140-1145, 1994.